JP2013537416A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537416A5
JP2013537416A5 JP2013523624A JP2013523624A JP2013537416A5 JP 2013537416 A5 JP2013537416 A5 JP 2013537416A5 JP 2013523624 A JP2013523624 A JP 2013523624A JP 2013523624 A JP2013523624 A JP 2013523624A JP 2013537416 A5 JP2013537416 A5 JP 2013537416A5
Authority
JP
Japan
Prior art keywords
region
polypeptide
polypeptide according
amino acid
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013523624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537416A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/063857 external-priority patent/WO2012020096A1/en
Publication of JP2013537416A publication Critical patent/JP2013537416A/ja
Publication of JP2013537416A5 publication Critical patent/JP2013537416A5/ja
Pending legal-status Critical Current

Links

JP2013523624A 2010-08-13 2011-08-11 変異型Fc領域を含むモノマーポリペプチド及び使用方法 Pending JP2013537416A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37342110P 2010-08-13 2010-08-13
US61/373,421 2010-08-13
PCT/EP2011/063857 WO2012020096A1 (en) 2010-08-13 2011-08-11 Monomeric polypeptides comprising variant fc regions and methods of use

Publications (2)

Publication Number Publication Date
JP2013537416A JP2013537416A (ja) 2013-10-03
JP2013537416A5 true JP2013537416A5 (enExample) 2014-09-25

Family

ID=44630039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523624A Pending JP2013537416A (ja) 2010-08-13 2011-08-11 変異型Fc領域を含むモノマーポリペプチド及び使用方法

Country Status (6)

Country Link
US (1) US20130177555A1 (enExample)
EP (1) EP2603526A1 (enExample)
JP (1) JP2013537416A (enExample)
AU (1) AU2011288412A1 (enExample)
CA (1) CA2808154A1 (enExample)
WO (1) WO2012020096A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TR201802772T4 (tr) 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
WO2013138643A1 (en) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Soluble engineered monomeric fc
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
US10358492B2 (en) * 2012-09-27 2019-07-23 Merus N.V. Bispecific IgG antibodies as T cell engagers
JP6581505B2 (ja) * 2012-10-03 2019-09-25 ザイムワークス,インコーポレイテッド 重鎖および軽鎖ポリペプチドの対を定量化する方法
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR102545617B1 (ko) 2012-11-28 2023-06-20 자임워크스 비씨 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
EP2970508A4 (en) * 2013-03-15 2016-12-14 Permeon Biologics Inc GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE
ES2881306T3 (es) * 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
CN106661125B (zh) 2014-05-02 2021-10-01 动量制药公司 涉及工程化Fc构建体的组合物和方法
EA201692476A1 (ru) 2014-05-28 2017-07-31 Займворкс Инк. Модифицированные антигенсвязывающие полипептидные конструкции и их применение
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
DK3233907T3 (da) * 2014-12-19 2021-06-07 Genmab As Bispecifikke heterodimeriske proteiner hos gnavere
JP6895890B2 (ja) * 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗muc1* 抗体
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA2989116A1 (en) * 2015-06-12 2016-12-15 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
EP3345928B1 (en) 2015-07-10 2020-06-24 Merus N.V. Human cd3 binding antibody
CA3000869A1 (en) 2015-10-08 2017-04-13 Zymeworks Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Fc領域含有ポリペプチドの精製を効率化するための方法
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
EP3431102A4 (en) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
MA45473A (fr) 2016-04-04 2019-02-13 Shire Human Genetic Therapies Inhibiteur de c1 estérase conjugué et ses utilisations
JP7320943B2 (ja) 2016-04-28 2023-08-04 中外製薬株式会社 抗体含有製剤
KR102635635B1 (ko) 2016-05-23 2024-02-14 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
CA3025162A1 (en) 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
DK3478830T3 (da) 2016-07-01 2024-05-21 Resolve Therapeutics Llc Optimerede binucleasefusioner og metoder
WO2018016881A1 (ko) * 2016-07-19 2018-01-25 (주)아이벤트러스 이중 특이성 단백질 및 이의 제조 방법
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
EP3573640A4 (en) * 2017-01-30 2021-04-28 The Ohio State Innovation Foundation PASSIVE ANTIBODY DEPENDENT CELLULAR MEDIATION ACTIVATION
EP3576789B1 (en) * 2017-02-01 2024-12-11 Zhejiang Shimai Pharmaceutical Co., Ltd. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
TW201834688A (zh) 2017-02-24 2018-10-01 日商中外製藥股份有限公司 藥學組成物、抗原結合分子、治療方法以及篩選方法
WO2018217947A1 (en) * 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and a tumor-associated antigen
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
JP7374091B2 (ja) 2017-08-22 2023-11-06 サナバイオ, エルエルシー 可溶性インターフェロン受容体およびその使用
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
EP4316502A3 (en) * 2018-04-17 2024-08-07 Heidelberg Biotech GmbH Means and methods for the treatment of angiogenesis-, fibrosis- and cancer-related diseases with protein oligomers comprising nc-1-fc
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
JP7523349B2 (ja) * 2018-08-29 2024-07-26 中外製薬株式会社 抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
MX2021007680A (es) * 2018-12-27 2021-10-13 Kindred Biosciences Inc Variantes de igg fc para uso veterinario.
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CN116829193A (zh) * 2020-11-03 2023-09-29 昂科纳诺医药公司 治疗性pH响应性组合物
CN113321736B (zh) * 2020-12-30 2024-01-09 苏州复融生物技术有限公司 一种长效化白介素15融合蛋白及其制备方法和应用
JP2024503034A (ja) * 2021-01-11 2024-01-24 アディマブ, エルエルシー 優先的ch3ヘテロ二量体化のために操作されたバリアントch3ドメイン、それを含む多重特異性抗体、及びその作製方法
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CN113261566B (zh) * 2021-04-14 2022-03-11 湖南工业大学 一种碱式次氯酸镁负载金属有机框架抑菌剂的制备方法
EP4392461A4 (en) * 2021-08-24 2025-10-15 Sunshine Lake Pharma Co Ltd GDF15 FUSION PROTEINS AND THEIR USES
WO2025108310A1 (zh) * 2023-11-20 2025-05-30 江苏恒瑞医药股份有限公司 通过重组反应制备异源多聚体的方法
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US20040010810A1 (en) 1990-01-12 2004-01-15 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
JPH06506105A (ja) 1990-08-29 1994-07-14 ファーミング ビーブイ 哺乳動物細胞における相同性組換え
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US6291591B1 (en) 2000-04-13 2001-09-18 Bridgestone Corporation Process for producing blends of syndiotactic 1,2-polybutadiene and rubbery elastomers with a chromium-based catalyst system
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
AU2003221888B2 (en) 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
AU2004215489B2 (en) 2003-02-25 2010-07-15 Nykode Therapeutics ASA Modified antibody
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007005786A2 (en) 2005-06-30 2007-01-11 Centocor, Inc. Methods and compositions with enhanced therapeutic activity
CA2614181A1 (en) * 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
CA2627981A1 (en) 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007084922A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
EP2087111A2 (en) * 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP3153524B1 (en) * 2008-12-03 2025-04-23 Genmab A/S Antibody variants having modifications in the constant region
EP2504360B1 (en) * 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
GB2476671B (en) 2010-01-04 2014-11-26 Plastic Logic Ltd Touch-sensing systems
JP5240316B2 (ja) 2010-10-26 2013-07-17 株式会社デンソー 車両乗員非操作運転システム
RU2604490C2 (ru) * 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
CN103459572A (zh) 2011-04-05 2013-12-18 雪佛龙奥伦耐有限责任公司 低粘度船用气缸润滑油组合物

Similar Documents

Publication Publication Date Title
JP2013537416A5 (enExample)
TWI868050B (zh) 用於改良儲存及投與之包含雙特異性抗體構築體之醫藥組成物
CA2896888C (en) Anti-tnf-anti-il-17 bispecific antibodies
DK2536764T3 (en) ANTI-CD28 HUMANIZED ANTIBODIES
JP2014519830A5 (enExample)
TWI671315B (zh) 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JP6647208B2 (ja) 抗il−17抗体、その生産および使用のための方法
JP7261307B2 (ja) 新規二重特異性cd3/cd20ポリペプチド複合体
JP2020018301A (ja) FcRnに特異的な抗体
US20230250133A1 (en) Methods of purifying a product
RU2018107427A (ru) Однодоменное антитело и его производные белки к лиганду-1 белка программируемой смерти клеток(pdli)
JP2018510617A5 (enExample)
JP7292526B2 (ja) 操作された抗il-2抗体
JP7097293B2 (ja) ヒトFc受容体に結合する融合タンパク質
PH12014502333B1 (en) Anti-baff-anti-il-17 bispecific antibodies
JP2014530001A5 (enExample)
CN116323671A (zh) 具有增加的选择性的多靶向性双特异性抗原结合分子
HRP20240102T1 (hr) Monoklonsko protutijelo koje antagonizira i inhibira vezanje između humanog pd-1 antigena i njegovog liganda, postupak njegove priprave i primjena
AU2021274522B2 (en) Methods and means for the production of Ig-like molecules
WO2022166728A1 (zh) 双特异性抗体
RU2019123112A (ru) Анти-il-5 антитела
HRP20161096T1 (hr) Antigenski vežući proteini specifični za komponentu p serumskog amiloida
TW202027788A (zh) 雙特異性抗體構建體之下游加工
JP2019518473A5 (enExample)
JPWO2022166728A5 (enExample)